<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>CD137 ligand (4-1BB ligand, TNFSF9, CD137L) is a member of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor family whose binding to its receptor, CD137 (4-1BB, TNFRSF9), mediates costimulatory and prosurvival signals necessary for T-cell activation and regulation of humoral immune responses </plain></SENT>
<SENT sid="1" pm="."><plain>Recent studies have shown that anti-CD137 immunotherapy has promise as a treatment for <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> and lymphoid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> in preclinical models </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we define the tissue expression profile of CD137L, which has not been previously explored </plain></SENT>
<SENT sid="3" pm="."><plain>We characterized the expression of CD137L in <z:mpath ids='MPATH_458'>normal</z:mpath> and neoplastic human hematopoietic and nonhematopoietic tissue and found that CD137L is preferentially expressed in B cells of the primary follicles, mantle zones of the secondary follicles, germinal centers, and in <z:mpath ids='MPATH_458'>normal</z:mpath> endothelial cells </plain></SENT>
<SENT sid="4" pm="."><plain>Double immunofluorescence labeling in tissue sections and flow cytometry analysis further showed that CD137L is a potential new marker of memory B cells </plain></SENT>
<SENT sid="5" pm="."><plain>Evaluation of over 700 human <z:e sem="disease" ids="C0376544" disease_type="Neoplastic Process" abbrv="">hematopoietic tumors</z:e> revealed that the majority of B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> expressed CD137L, which include mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>In contrast, CD137L expression was lacking in Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Our findings suggest that CD137L is a novel diagnostic marker of subtypes of non-Hodgkin B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and raise the possibility that its expression on <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells may be directly targeted for immunomodulatory therapy for lymphoid and other <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
</text></document>